Pharmacokinetic interaction between rhynchopylline and pellodendrine via CYP450 enzymes and
            <i>P-gp</i>

Meng, Qingzhen; Cheng, Yongheng; Zhou, Cui

doi:10.1080/13880209.2021.1999988

Cited by 6 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Caco‐2 cell models could mimic the in vivo transport of various compounds, and it is also a critical method in herb‐herb interaction. For instance, a pharmacokinetic study investigated the interaction between rhynchopylline and pellodendrine and observed the inhibited transport of pellodendrine with a decreasing efflux rate (Meng et al, 2021). Similarly, ophiopogonin D was found to suppress the permeability of cryptotanshinone in Caco‐2 cells indicated by the decreasing efflux rate.…”

Section: Discussionmentioning

confidence: 99%

Effect of ophiopogonin D on the pharmacokinetics and transport of cryptotanshinone during their co‐administration and the potential mechanism

Wang

Chen

2023

Chem Biol Drug Des

View full text Add to dashboard Cite

Cryptotanshinone and ophiopogonin D are sourced from herbs with similar indications. It is necessary to evaluate their interaction to provide a reference for their clinical prescriptions. The co‐administration of cryptotanshinone (30 and 60 mg/kg) and ophiopogonin D was carried out in Sprague–Dawley rats and the pharmacokinetics of cryptotanshinone were analyzed. The Caco‐2 cells were employed to evaluate the transport of cryptotanshinone, and the metabolic stability was studied in the rat liver microsomes. Ophiopogonin D significantly increased the Cmax (from 5.56 ± 0.26 to 8.58 ± 0.71 μg/mL and from 15.99 ± 1.81 to 185.12 ± 1.43 μg/mL), half‐life (21.72 ± 10.63 vs. 11.47 ± 3.62 h and 12.58 ± 5.97 vs. 8.75 ± 2.71 h) and decreased the clearance rate (0.697 ± 0.36 vs. 1.71 ± 0.15 L/h/kg) and (60 mg/kg and 0.101 ± 0.02 vs. 0.165 ± 0.05 L/h/kg) of cryptotanshinone. In vitro, ophiopogonin D significantly suppressed the transport of cryptotanshinone with the decreasing efflux rate and enhanced the metabolic stability with the reducing intrinsic clearance. The combination of cryptotanshinone and ophiopogonin D induced prolonged exposure and suppressed the transport of cryptotanshinone, which indicated the decreased bioavailability of cryptotanshinone.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of ophiopogonin D on the pharmacokinetics and transport of cryptotanshinone during their co‐administration and the potential mechanism

Wang

Chen

2023

Chem Biol Drug Des

View full text Add to dashboard Cite

show abstract

“…Previously, the activity of cytochromes P450 enzymes (CYP450s) was widely accepted as an important factor responsible for drug-drug interaction and has been illustrated to mediate the interaction between various drugs or compounds. For example, CYP1A2 and CYP2C9 were two critical CYP450 isoforms involved in the metabolism of rhynchopylline, while the inhibition of these two CYP450s by pellodendrine resulted in the increased plasma concentration of rhynchopylline, which implied an adverse interaction between these two compounds and their origins (Meng et al, 2021). Similarly, the inhibitory effect of anemarsaponin BII on CYP3A4 led to its interaction with nobiletin, an extraction of Citrus reticulata Blanco (Rutaceae) metabolized by CYP3A4 (Zhang et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic study of the interaction between luteolin and magnoflorine in rats

Liu,

2023

Chem Biol Drug Des

View full text Add to dashboard Cite

Both luteolin and magnoflorine have been reported to regulate the development of breast cancer, which makes them easier to co‐administrate. Luteolin was co‐administrated with magnoflorine to evaluate their potential interaction. The pharmacokinetic study was performed on male Sprague–Dawley rats randomly grouped as the single administration of luteolin and the co‐administration of luteolin and magnoflorine with six rats of each. CaCO‐2 cell transwell assay was employed for transport evaluation, and the metabolic stability of luteolin and CYP3A activity were assessed in rat liver microsomes. The effect of luteolin on MDA‐MB‐231 cells was assessed with CCK8 assay. Magnoflorine significantly changed the pharmacokinetic profile of luteolin with increased area under the curve (AUC), prolonged t1/2, and reduced clearance rate. Magnoflorine also suppressed the efflux ratio and improved the in vitro metabolic stability of luteolin. Magnoflorine also enhanced the inhibitory effect of luteolin on MDA‐MB‐231 cells. Magnoflorine significantly inhibited CYP3A activity with the IC50 of 18.99 μM. Magnoflorine prolonged the system exposure, enhanced the metabolic stability, and enhanced the anti‐tumor effect of luteolin through inactivating CYP3A.

show abstract

“…The liver is the main organ for drug metabolism and excretion, and liver drug metabolism enzymes play an important role in drug disposal, clinical e cacy, and toxicity [13]. CYP450 is the most important metabolic enzyme involved in drug metabolism, as well as a combination of different drugs [14]. According to its gene sequence and homology, CYP450 has a large family and subfamily of enzymes, among which there are three major families of CYP450 enzymes involved in drug metabolism, namely CYP1, 2, and 3 families.…”

Section: Introductionmentioning

confidence: 99%

Astragalus injection alters the pharmacokinetics of doxorubicin and affects the activity of CYP450 enzymes

Shi

Tian

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Doxorubicin (DOX) is an antitumor antibiotic widely used in the treatment of breast cancer, liver cancer, lymphoma and other malignant tumors. However, its clinical application is limited by the side effects and drug resistance. Astragalus injection has been combined with DOX in the treatment of cancer, which can improve the curative effect and reduce drug resistance. This study investigated the interaction between DOX and Astragalus injection and elucidated the potential mechanism. Methods The pharmacokinetics of DOX injection (7 mg/kg) with or without Astragalus injection (4.25 mL/kg/day for 14 days) were investigated in male Sprague-Dawley rats (n = 6) by UPLC-MS/MS. The group without the Astragalus injection was set as the control group. Additionally, Sprague-Dawley rat liver microsomes incubation systems were employed to assess the effects of Astragalus injection on CYP450 enzymes. Results Astragalus injection significantly increased the Cmax (2090.01 ± 99.60 vs. 5262.77 ± 111.15 ng/mL) and AUC0-t (1190.23 ± 104.43 vs. 3777.27 ± 130.55 µg/L × h) and prolonged the t1/2α (0.09 ± 0.02 vs. 0.14 ± 0.04 h) of DOX. Astragalus injection significantly inhibited the activity of CYP1A2, CYP2C9, CYP2E1, and CYP3A4, and enhanced the activity of CYP2D1 with a metabolic elimination rate of 30.11 ± 2.67% vs 19.66 ± 3.41%, 35.95 ± 2.57% vs 23.26 ± 3.57%, 13.43 ± 2.56% vs 9.06 ± 2.51%, 47.90 ± 6.30% vs 25.87 ± 2.55%, 17.62 ± 1.49% vs 24.12 ± 2.91%, respectively (p < 0.05). Conclusions The co-administration of DOX and Astragalus injection alters the system exposure of DOX, possibly by affecting the metabolism of DOX by affecting the activity of CYP450 enzymes. Further clinical studies could be carried out according to the investigation.

show abstract

Pharmacokinetic interaction between rhynchopylline and pellodendrine via CYP450 enzymes and P-gp

Cited by 6 publications

References 20 publications

Effect of ophiopogonin D on the pharmacokinetics and transport of cryptotanshinone during their co‐administration and the potential mechanism

Effect of ophiopogonin D on the pharmacokinetics and transport of cryptotanshinone during their co‐administration and the potential mechanism

Pharmacokinetic study of the interaction between luteolin and magnoflorine in rats

Astragalus injection alters the pharmacokinetics of doxorubicin and affects the activity of CYP450 enzymes

Contact Info

Product

Resources

About